Revvity Inc. (NYSE:RVTY) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Revvity Inc. (NYSE:RVTY) have received a consensus recommendation of “Hold” from the fourteen ratings firms that are currently covering the company, Marketbeat.com reports. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $113.6667.

Several research analysts have weighed in on the stock. Barclays upped their price objective on shares of Revvity from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Tuesday, February 3rd. Wall Street Zen upgraded shares of Revvity from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Robert W. Baird set a $129.00 price target on shares of Revvity in a research note on Tuesday, February 3rd. Bank of America lowered Revvity from a “buy” rating to a “neutral” rating and set a $110.00 price objective for the company. in a report on Monday, December 15th. Finally, Evercore lifted their price objective on Revvity from $112.00 to $118.00 and gave the company an “outperform” rating in a research report on Tuesday, February 3rd.

Revvity Trading Up 1.0%

NYSE:RVTY opened at $85.60 on Monday. The stock has a market cap of $9.57 billion, a PE ratio of 41.15, a price-to-earnings-growth ratio of 1.82 and a beta of 1.10. Revvity has a fifty-two week low of $81.36 and a fifty-two week high of $118.30. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.68 and a quick ratio of 1.40. The stock’s 50-day moving average is $102.27 and its two-hundred day moving average is $96.59.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, February 2nd. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. The business had revenue of $772.06 million during the quarter, compared to analyst estimates of $759.81 million. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.42 earnings per share. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. As a group, equities research analysts forecast that Revvity will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 8th. Stockholders of record on Friday, April 17th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Friday, April 17th. Revvity’s payout ratio is currently 13.46%.

Institutional Investors Weigh In On Revvity

Several large investors have recently made changes to their positions in the company. New York Life Investment Management LLC grew its position in Revvity by 72.7% in the third quarter. New York Life Investment Management LLC now owns 27,520 shares of the company’s stock worth $2,412,000 after acquiring an additional 11,583 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new position in shares of Revvity during the 3rd quarter valued at $905,000. Amundi raised its holdings in shares of Revvity by 157.0% during the 2nd quarter. Amundi now owns 519,987 shares of the company’s stock valued at $52,467,000 after purchasing an additional 317,643 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Revvity by 25.8% in the 2nd quarter. Invesco Ltd. now owns 2,207,202 shares of the company’s stock valued at $213,481,000 after purchasing an additional 452,343 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Revvity by 531.8% in the 3rd quarter. SG Americas Securities LLC now owns 42,947 shares of the company’s stock valued at $3,764,000 after purchasing an additional 36,149 shares during the last quarter. Institutional investors own 86.65% of the company’s stock.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.